

# Wen-Hai Shao

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4500828/publications.pdf>

Version: 2024-02-01

20  
papers

571  
citations

687363

13  
h-index

794594

19  
g-index

20  
all docs

20  
docs citations

20  
times ranked

827  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Akt-mTORC1 pathway mediates Axl receptor tyrosine kinase-induced mesangial cell proliferation. <i>Journal of Leukocyte Biology</i> , 2022, 111, 563-571.	3.3	4
2	Epigenetic Alterations in Immune Cells of Systemic Lupus Erythematosus and Therapeutic Implications. <i>Cells</i> , 2022, 11, 506.	4.1	16
3	Axl Expression in Renal Mesangial Cells Is Regulated by Sp1, Ap1, MZF1, and Ep300, and the IL-6/miR-34a Pathway. <i>Cells</i> , 2022, 11, 1869.	4.1	1
4	Ezh2-mediated epigenetic modification is required for allogeneic T cell-induced lupus disease. <i>Arthritis Research and Therapy</i> , 2020, 22, 133.	3.5	22
5	Gas6/TAM Receptors in Systemic Lupus Erythematosus. <i>Disease Markers</i> , 2019, 2019, 1-9.	1.3	21
6	Experimental Analysis of Apoptotic Thymocyte Engulfment by Macrophages. <i>Journal of Visualized Experiments</i> , 2019, , .	0.3	4
7	Mechanism of Mer receptor tyrosine kinase inhibition of glomerular endothelial cell inflammation. <i>Journal of Leukocyte Biology</i> , 2018, 103, 709-717.	3.3	11
8	Targeted inhibition of Axl receptor tyrosine kinase ameliorates anti-GBM-induced lupus-like nephritis. <i>Journal of Autoimmunity</i> , 2018, 93, 37-44.	6.5	25
9	Opposing Roles of Tyrosine Kinase Receptors Mer and Axl Determine Clinical Outcomes in Experimental Immune-Mediated Nephritis. <i>Journal of Immunology</i> , 2016, 197, 2187-2194.	0.8	23
10	The Role of Microparticles in Rheumatic Diseases and their Potentials as Therapeutic Tools. , 2016, 1, .		3
11	Stat1 Regulates Lupus-like Chronic Graft-versus-Host Disease Severity via Interactions with Stat3. <i>Journal of Immunology</i> , 2015, 195, 4136-4143.	0.8	16
12	The role of tyrosine kinases in systemic lupus erythematosus and their potential as therapeutic targets. <i>Expert Review of Clinical Immunology</i> , 2014, 10, 573-582.	3.0	24
13	The Mer receptor tyrosine kinase promotes T-B interaction stimulated by IgD B-cell receptor cross-linking. <i>Journal of Autoimmunity</i> , 2014, 53, 78-84.	6.5	8
14	Intrinsic unresponsiveness of Mer <sup>-/-</sup> B cells to chronic graft-versus-host disease is associated with unmodulated CD1d expression. <i>Journal of Autoimmunity</i> , 2012, 39, 412-419.	6.5	4
15	A protective role of Mer receptor tyrosine kinase in nephrotoxic serum-induced nephritis. <i>Clinical Immunology</i> , 2010, 136, 236-244.	3.2	27
16	Impaired Apoptotic Cell Clearance in the Germinal Center by Mer-Deficient Tingible Body Macrophages Leads to Enhanced Antibody-Forming Cell and Germinal Center Responses. <i>Journal of Immunology</i> , 2010, 185, 5859-5868.	0.8	86
17	Disrupted Mer receptor tyrosine kinase expression leads to enhanced MZ B-cell responses. <i>Journal of Autoimmunity</i> , 2010, 35, 368-374.	6.5	24
18	Disturbances of apoptotic cell clearance in systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2010, 13, 202.	3.5	158

#	ARTICLE	IF	CITATIONS
19	The Mer receptor tyrosine kinase is expressed on discrete macrophage subpopulations and mainly uses Gas6 as its ligand for uptake of apoptotic cells. <i>Clinical Immunology</i> , 2009, 133, 138-144.	3.2	58
20	The Mer Receptor Tyrosine Kinase Is Required for the Loss of B Cell Tolerance in the Chronic Graft-versus-Host Disease Model of Systemic Lupus Erythematosus. <i>Journal of Immunology</i> , 2008, 180, 7728-7735.	0.8	36